AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Jun 30, 2025
30604_dirs_2025-06-30_d10064e3-be87-42db-b2dd-3f7507ab7fc7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-06-26
Reporting Person: Valantine Hannah (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-26 | Common Stock | S | 876 | $44.1099 | Disposed | 9007 | Direct |
| 2025-06-26 | Common Stock | S | 1542 | $44.01 | Disposed | 7465 | Direct |
| 2025-06-26 | Common Stock | S | 398 | $44.1263 | Disposed | 2289 | Indirect |
| 2025-06-26 | Common Stock | S | 1891 | $44.0303 | Disposed | 398 | Indirect |
Footnotes
F1: Represents the weighted average sale price of the shares sold from $44.025 to $44.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F2: Represents the weighted average sale price of the shares sold from $44.12 to $44.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.